The Week in Review: March 23 – April 6, 2018

Friday, April 6, 2018 News Recap: HCV – Liver Cancer (HCC): Liver Cancer on the Rise in Backdrop of Undiagnosed Hep C. Liver cancer, one of the greatest challenges to hepatologists today, will be in the spotlight at the upcoming International Liver Congress (ILC) 2018. It will become an even greater challenge in the near future, said Morris Sherman, PhD, from the University of Toronto, who is chair of the Canadian Liver Foundation. Testing for he...

Conatus Pharma’s Liver Disease Drug Flunks First Phase 2 Test

A Conatus Pharmaceuticals drug developed as a treatment for chronic liver disease has failed to beat a placebo in a mid-stage study, the first of four underway for the drug. Conatus (NASDAQ: CNAT) tested its drug, emricasan, in liver transplant patients whose hepatitis C virus has cleared, but who still have fibrosis or cirrhosis in the transplanted organ. The drug is meant to reduce the activity of enzymes that play a role in inflammation and cell death.